These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6800852)

  • 1. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
    Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
    Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
    Faure N; Labrie F; Belanger A; Lemay A; Raynaud JP; Von der Ohe M; Fazekas AT
    J Endocrinol Invest; 1982; 5(6):355-60. PubMed ID: 6820372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
    Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic treatment with a potent luteinizing hormone releasing hormone agonist on serum luteinizing hormone and steroid levels in the male rhesus monkey.
    Resko JA; Belanger A; Labrie F
    Biol Reprod; 1982 Apr; 26(3):378-84. PubMed ID: 7044432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women.
    Lemay A; Faure N; Labrie F
    Fertil Steril; 1982 Feb; 37(2):193-200. PubMed ID: 6800846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
    Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
    Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1983 May; 39(5):661-7. PubMed ID: 6404660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
    Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
    Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.
    Lacoste D; St-Arnaud R; Caron S; Belanger A; Labrie F
    J Steroid Biochem; 1988 Dec; 31(6):963-70. PubMed ID: 3059065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
    Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
    Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the chronic administration of a potent luteinizing hormone releasing hormone analog on the rat prostate.
    Trachtenberg J
    J Urol; 1982 Nov; 128(5):1097-100. PubMed ID: 6294350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the luteinizing hormone-releasing activities of synthetic chicken luteinizing hormone-releasing hormone (LH-RH), synthetic porcine LH-RH, and buserelin, an LH-RH analogue, in the domestic fowl.
    Sterling RJ; Sharp PJ
    Gen Comp Endocrinol; 1984 Sep; 55(3):463-71. PubMed ID: 6432627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
    Huhtaniemi I; Nikula H; Rannikko S
    J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
    Wenderoth UK; Happ J; Krause U; Adenauer H; Jacobi GH
    Eur Urol; 1982; 8(6):343-7. PubMed ID: 6814918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.